Open Nav

Cross-Border M&A—Takeda/Nycomed

Tuesday, January 31st, 9:30am-10:25am

Nominated to be IN VIVO Blog’s M&A  Deal of the Year for 2011, Takeda’s $13.7B acquisition of Nycomed is the largest cross-border transaction by a Japanese company and provided Takeda with greater infrastructure in Europe, an immediate entry into emerging markets, and an immediate increase in cash flow. The deal provided a hefty return to Nycomed investors, and even yielded a coveted “Private Equity Deal of the Year” award at the European M&A awards for primary investor Nordic Capital. This deal both expands Takeda’s global footprint and reinforces Japan’s global leadership in the biopharma industry. Senior executives crucial to the execution of this stellar deal will conduct a deep-dive on the deal terms and integration process.


  • David Low, Managing Director, Life Sciences Group, Lazard


  • Ken Araki, Vice President, Head of Global Corporate Development and Japan BD Group
    Global Business Development, Takeda Pharmaceutical Company Limited
  • Gunnar Gårdemyr, Senior Vice President, Head of Global Licensing Business Development Operations, Takeda Pharmaceuticals International

Who's Who

Ken Araki 
Vice President, Head of Global Corporate Development and Japan BD Group
Global Business Development, Takeda Pharmaceutical Company Limited

Since January 2012, Ken Araki has managed Takeda’s global corporate development activities, including M&A and the Japan Business Development group in charge of Japan/North Asia local transactions and global discovery research collaborations.

Prior to Ken’s current role, he initiated and managed global corporate-wide strategic projects in Takeda’s Corporate Strategy and Planning Department, supporting Takeda’s Senior Management team including the President & CEO. While in this role from 2009 to 2011, he successfully executed the acquisition of Nycomed and was involved in integrating the company into Takeda’s organization. Ken joined Takeda in 2006 as Head of M&A. During his tenure, he successfully executed the acquisition of Millennium Pharmaceuticals and its subsequent integration into Takeda’s organization.

Prior to joining Takeda, he worked on the Investment Banking team at Nomura Securities, the largest firm in Japan. During his tenure, he acted as financial advisor, helping create Daiichi-Sankyo, one of Japan’s largest pharmaceutical companies. He spent over ten years at Nomura as a sell-side analyst, gaining extensive experience as he analyzed the pharmaceutical and biotech industries globally and allowing him to produce many writings and lectures on the industry. He also played a central role in Global Pharmaceutical Equity Research in New York between 1996 and 2004. From 1989 to 1996 he held a series of positions with Nomura Research Institute, a subsidiary of Nomura Securities, including the position of equity analyst following the electronics industry.

Ken holds a Bachelor of Law degree from Kyushu University. He is married with two young daughters and his favorite hobby is spending time with his family.

Gunnar Gårdemyr
VP, Head of Global Licensing Business Development Operations, Takeda Pharmaceuticals International
Gunnar Gårdemyr is Head, Operations, for Global Licensing & Business Development at Takeda. He has worked in the pharmaceutical business for the past 30 years. Gunnar has a broad range of experience in global marketing, leadership, financing and business development. He has held various senior and executive positions with AstraZeneca, Ferring and Nycomed prior to joining Takeda. Gunnar managed the Nycomed acquisition of Altana in 2007 as well as the acquisitions of Bradley, USA, Techpool, China and Farmacol, Colombia. Gunnar was recently coordinating the divestment of Nycomed to Takeda.

David Low
Managing Director, Life Sciences Group, Lazard
Mr. Low joined Lazard's Life Sciences Group in 2002 as a Managing Director based in San Francisco. Mr. Low has had a long career in Biotech M&A, advising on transactions including Roche’s restructuring of its Genentech ownership (1995 and 1999/2000), Johnson & Johnson’s acquisition of Centocor (1999) and Gilead’s acquisition of Myogen (2006), and Onyx Pharmaceuticals’ acquisition of Proteolix (2009) among others. On the financing side, Mr. Low has extensive experience with debt and equity, convertibles, R&D financings, private placements and royalty transactions for biotech companies.